İrem UZUN -TDO- Final clinical trials for a coronavirus vaccine, developed by AstraZeneca and Oxford University, have been put on hold after a participant had a suspected adverse reaction in the U.K. "Our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," the company said in a statement. "This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials."
The AstraZeneca-Oxford University vaccine is seen as a strong contender among dozens being developed globally. The outcome of trials is being closely watched around the world. The hope for this vaccine is high and many believe it might be one of the first to come on the market. Some 30,000 participants in the U.S. as well as in the U.K., Brazil and South Africa got involved in the Phase 3 testing in recent weeks.
The nature and severity of the volunteer’s illness is not clear. According to The New York Times, the participant is from the United Kingdom and was found to have transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections.